MilliporeSigma, a global leader in the life sciences industry, has announced its acquisition of Mirus Bio, a Madison-based manufacturer of transfection regents used in gene therapies. The deal is valued at $600 million and is set to close in the third quarter of this year.
Mirus Bio’s CEO, Dale Gordon, expressed excitement about the acquisition, stating that MilliporeSigma’s broad portfolio, scale, and global reach will help take their business to new heights. He believes that the acquisition will allow them to serve more customers and patients worldwide.
MilliporeSigma’s Process Solutions business provides solutions for viral vector manufacturing, catering to cell and gene therapies from preclinical through commercial production. Their portfolio includes cell lines, culture media, processing chemicals, enzymes, and various systems and consumables essential for viral vector manufacturing processes. This makes them a valuable addition to Mirus Bio’s offerings in the field of cell and gene therapies.
In addition to manufacturing solutions, MilliporeSigma’s Life Science Services business offers contract testing and contract development and manufacturing organization services specifically for viral vector manufacturing. Matthias Heinzel, CEO of the Life Science business at Merck KGaA, emphasized the growing demand for viral vector-based therapies, projecting a 30% growth until 2028. This further strengthens MilliporeSigma’s position as a leader in the field of life sciences.
Overall, this acquisition marks an important milestone for both companies in expanding their offerings in the field of cell and gene therapies. It also highlights the growing demand for these types of treatments and the importance of providing high-quality solutions to support their development and production.
